All In Biotech

Investigational drug · Phase 2

Keynatinib

Also called: TL007

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

2

Any phase or sponsor naming "Keynatinib"

First trial start

2020

Oct 21, 2020

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Keynatinib", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-Small Cell Lung Cancer With EGFR Mutation
  • Brain Metastases

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "Keynatinib" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Non-Small Cell Lung Cancer With EGFR Mutation

  • FirmonertinibAST2818Phase 34 trials

    Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer

  • ABSK043Phase 24 trials

    Abbisko Therapeutics Co, Ltd · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive, HER2-Gastric/Gastroesophageal Junction Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.